Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. - Wikidata - awgldk - TriplyDB

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

http://www.wikidata.org/entity/Q40907444

about

Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis Management of HCV-Associated Liver Cirrhosis.Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease Hepatitis C virus: Promising discoveries and new treatments Sofosbuvir/velpatasvir: A promising combination Approved Antiviral Drugs over the Past 50 Years Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline Treatment optimization for HIV/HCV co-infected patients.Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.Hepatitis C virus infection.Hepatitis C genotype 3 disease.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.Hepatitis C treatment: where are we now?Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current Therapies Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting.Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Direct-acting antivirals for chronic hepatitis C.Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies New perspectives for preventing hepatitis C virus liver graft infection.Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India.A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies.Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin.Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.HCV management in resource-constrained countries.Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens.Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.

P2860

Q26740313-5B33EF30-6E10-40CE-9968-3C0557F3E442 Q26740320-B77B5DD3-6615-4F85-A015-455884905B0C Q26747705-118D8DEC-B831-4F89-A33E-9AF7D735E89C Q26749246-34C0AA13-047A-490A-9370-8D3E19333E66 Q26751452-29C37A52-120A-418F-9610-02E3C7610474 Q26752433-1643AB35-3D6C-4FE8-AC39-3AC412E7DF15 Q27468916-C6F47875-4C0C-48D8-8342-556ACFFACCBE Q27468954-3F62283E-8FE1-4697-A214-DC76B9C89FB1 Q27755387-B059B5EF-81A7-45E8-8408-F1014AA507B6 Q28075544-784C9190-5B08-49DF-B1DF-A190CE579D01 Q28076883-F6D20FB1-51C0-483C-AF41-27659A35DAA5 Q30235034-C7EF41EC-5181-4C98-B111-325C32E15B0E Q30235178-00EB64CC-FD93-4EF4-9866-8852813E850F Q30235430-8CD81597-0790-40C6-BC1D-0FC03E15F2E0 Q30235491-80176603-30CF-4A87-95BE-A0A73F13A7F8 Q30244065-F37230F6-4CD3-4B0A-BED2-602F8A39C775 Q30250322-F48C533B-81EF-4C5A-B039-6DB3FFA14C6E Q30251847-AB2ED242-1AFC-43FD-922E-6796BD3981D3 Q30378509-041EF502-6CE0-4BCB-A9A4-70C61B6C256C Q31051529-F3F78101-F02D-467B-A833-3F870FDB17EB Q33440130-7EC73E7D-C3A1-4471-8F7B-442FF72F8511 Q33560181-9BDCDD0D-C33E-46DB-A591-28AE6612B7C7 Q33585021-234686A2-9E95-4449-A7FD-698E60B25985 Q33805907-576B29A2-9A04-4779-9D4D-0E2EA90CD76C Q34522481-2B2C8BDC-AD9F-4E96-87CB-1BC73BF9D2FE Q34557595-CC7D5696-EC1C-4898-BEA6-D6EC758E5A41 Q36214085-90CFB24E-611F-4EBF-A9DD-5609E3C5211E Q36981033-CD126562-2561-48D3-BBCF-B9E878877E32 Q37015805-6D6FB6AD-8DE8-478D-BF9C-611CA406DBA7 Q37055231-C26F56BB-E360-4E89-96CA-44C8A02BB41B Q37089469-9F973FD9-4D33-4437-AD09-F67E40DC0F3A Q37279260-75BAB674-BADC-4301-BCBD-A9DF911353CF Q37298739-BE67B233-36B3-4FA4-B83D-2BB32256B813 Q37349005-C192A64E-A18E-4670-AB33-C308EEFDDA79 Q37555313-6D40506E-375D-4B74-8432-D7E2E117F941 Q37563692-0DC8F5E6-0A55-4D86-9166-5F9D1CD68380 Q38372939-F2D031A7-C083-4C5C-B73D-932BD59A849A Q38618427-118A96AE-2516-4022-A417-2408A4B81526 Q38677852-043C268F-AA52-46C1-8694-E5D454BB44B2 Q38728564-F1BB7BFA-8D90-4F76-B342-7D1A50800669

P2860

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

http://www.wikidata.org/entity/Q40907444

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

@en

type

label

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

@en

prefLabel

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

@en

P1433

Q40907444-0C227617-AF48-40A4-A8AE-D6D7D023D16E

P1476

Q40907444-0A4940D9-4F3D-4CEC-A644-8CA15AB49FA2

P2093

Q40907444-1187971B-569B-4B13-A2B4-1738B279397F

Q40907444-13CCCB29-AAA4-4FEA-A2D5-C3CECA4EA49C

Q40907444-25D0E0B2-88AA-4CA9-8554-B7AE8FA59CD5

Q40907444-2B30E2A2-8737-4E69-9F42-5D1BFB9660A8

Q40907444-333FA72E-DB58-4416-AB3D-EE0D806D1DAD

Q40907444-39B9A9CA-669C-47BE-9F10-35F1FB05F50E

Q40907444-4152B7E0-66A1-40BF-9A6B-D4C327421ECC

Q40907444-50B8F1F5-3B52-4B1E-896C-444B250BBAFE

Q40907444-529AAE76-DC65-4542-8083-DA21C017F420

Q40907444-5C290F76-169F-4E30-9EF5-EF64DC2FA692

P304

Q40907444-4834472C-BC16-4AC6-BD8E-35CEC98BBE44

P31

Q40907444-FEA4C9F3-3188-409D-AFBC-D030D1B8BA83

P356

Q40907444-4C6C1321-1AC2-4CCD-9053-DF62C88E4EBB

P407

Q40907444-92F8B128-5AAF-4D7A-A5CA-63841C8A90FE

P433

Q40907444-A970909D-2932-459A-985B-A66B3E053C20

P478

Q40907444-C0B5EE1D-9737-45E6-9405-A2852831DE21

P50

Q40907444-0A2635EC-A6E4-41CB-9E7C-D7925E5B058B

Q40907444-7565CE87-3C19-40B2-9E80-F6756467AAA6

Q40907444-7A0B27BF-511D-493F-933C-13948B323D54

Q40907444-AAE4EE56-9063-4AA6-B241-AA088CE4F6D2

P577

Q40907444-672BA75B-5369-4841-8AC1-71FF7927E25E

P698

Q40907444-A0655B0A-BF3A-4A7B-BDBE-42723124C43B

P921

Q40907444-3457A417-F37B-4888-A66A-CB0109A71BFF

Q40907444-61C5F743-B186-46DD-A7D6-A4B017AEAB4F

P356

P1433

The New England Journal of Medicine

P1476

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

@en

P2093

ASTRAL-2 Investigators

http://www.w3.org/2001/XMLSchema#string

ASTRAL-3 Investigators

http://www.w3.org/2001/XMLSchema#string

Alessandra Mangia

http://www.w3.org/2001/XMLSchema#string

Alex Thompson

http://www.w3.org/2001/XMLSchema#string

Anu Osinusi

http://www.w3.org/2001/XMLSchema#string

Brian Conway

http://www.w3.org/2001/XMLSchema#string

Catherine A M Stedman

http://www.w3.org/2001/XMLSchema#string

Curtis Cooper

http://www.w3.org/2001/XMLSchema#string

Diana M Brainard

http://www.w3.org/2001/XMLSchema#string

Edward J Gane

http://www.w3.org/2001/XMLSchema#string

P304

2608-2617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1512612

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Hadas Dvory-Sobol

William Rosenberg

P577

2015-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26575258

http://www.w3.org/2001/XMLSchema#string

P921